14 research outputs found
Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin
Preparation of gluten-free rice spaghetti with soy protein isolate using twin-screw extrusion
Pathophysiology and Potential Clinical Applications for Testing of Peripheral Chemosensitivity in Heart Failure
Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients
Carotid body denervation improves autonomic and cardiac function and attenuates disordered breathing in congestive heart failure
Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies
Low ventilatory responsiveness to transient hypoxia or breath-holding predicts fast marathon performance in healthy middle-aged and older men
Diagnosis and management of resistant hypertension: state of the art.
Resistant hypertension is defined as a lack of ambulatory blood pressure response to optimized medical treatment after exclusion of secondary hypertension in patients who are fully adherent to antihypertensive therapy. Patients with resistant hypertension are at high risk of complications, particularly cardiovascular events, and optimization of medical treatment remains the cornerstone of their management. Such optimization should be based on simple algorithms and include the use of aldosterone antagonists. The available data from clinical trials do not support the use of device-based approaches such as renal denervation, baroreflex activation therapy or arteriovenous anastomosis for the treatment of resistant hypertension in the majority of patients. Therefore, device treatment remains a last-resort for patients with truly resistant hypertension in the context of clinical research in highly skilled tertiary referral centres. Future research should focus on improving understanding of the intrinsic (physiological and psychological factors) and extrinsic (environmental stressors) mechanisms that contribute to a lack of response to blood-pressure-lowering drugs in adherent patients. The use of biomarkers to identify patients with early target organ damage and new technologies, such as renal nerve stimulation, to predict blood pressure responses to renal denervation could aid the selection of patients who might benefit from device therapies